BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 19896693)

  • 41. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
    Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ovarian clear cell carcinoma with papillary features: a potential mimic of serous tumor of low malignant potential.
    Sangoi AR; Soslow RA; Teng NN; Longacre TA
    Am J Surg Pathol; 2008 Feb; 32(2):269-74. PubMed ID: 18223330
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
    Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
    Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors.
    Choi YL; Kim SH; Shin YK; Hong YC; Lee SJ; Kang SY; Ahn G
    Gynecol Oncol; 2005 May; 97(2):379-86. PubMed ID: 15863133
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ovarian serous borderline tumors with invasive peritoneal implants.
    Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
    Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Proliferative activity and p53 over-expression of ovarian epithelial tumors.
    Kuwata T; Kitagawa M; Takemura T; Hirokawa K
    Gen Diagn Pathol; 1995 Oct; 141(2):131-9. PubMed ID: 8548593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. u-PA expression in benign, borderline and malignant ovarian tumors.
    Kiziridou AD; Toliou T; Stefanou D; Agnantis N
    Anticancer Res; 2002; 22(2A):985-90. PubMed ID: 12014682
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma.
    Wang X; Wei Z; Gao F; Zhang X; Zhou C; Zhu F; Wang Q; Gao Q; Ma C; Sun W; Kong B; Zhang L
    Anticancer Res; 2008; 28(5B):2991-6. PubMed ID: 19031945
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bilateral micropapillary serous carcinoma of the ovary: a case report.
    Gupta R; Singh S; Nigam S
    Arch Gynecol Obstet; 2007 May; 275(5):401-4. PubMed ID: 17031658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patterns of low-grade serous carcinoma with emphasis on the nonepithelial-lined spaces pattern of invasion and the disorganized orphan papillae.
    Silva EG; Deavers MT; Malpica A
    Int J Gynecol Pathol; 2010 Nov; 29(6):507-12. PubMed ID: 20881864
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
    Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
    Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
    Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 May; 30(5):614-24. PubMed ID: 16699316
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of p16, p53, CD24, EpCAM and calretinin in serous borderline tumors of the ovary.
    Aktaş IY; Buğdayci M; Usubütün A
    Turk Patoloji Derg; 2012; 28(3):220-30. PubMed ID: 23011824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The presence and location of epithelial implants and implants with epithelial proliferation may predict a higher risk of recurrence in serous borderline ovarian tumors: a clinicopathologic study of 188 cases.
    Quddus MR; Sung CJ; Zhang C; Moore RG; Ou JJ; Steinhoff MM; Lawrence WD
    Hum Pathol; 2012 May; 43(5):747-52. PubMed ID: 22047646
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metaplastic papillary tumor of the salpinx: report of a case using microsatellite analysis.
    D'Adda T; Pizzi S; Bottarelli L; Azzoni C; Manni S; Giordano G
    Int J Gynecol Pathol; 2011 Nov; 30(6):532-5. PubMed ID: 21979587
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low-grade Serous Carcinoma of the Ovary: Clinicopathologic Analysis of 52 Invasive Cases and Identification of a Possible Noninvasive Intermediate Lesion.
    Ahn G; Folkins AK; McKenney JK; Longacre TA
    Am J Surg Pathol; 2016 Sep; 40(9):1165-76. PubMed ID: 27487741
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
    Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
    Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance].
    Shao SL; Cai Y; Wang QH; Yan LJ; Zhao XY; Wang LX
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):697-700. PubMed ID: 18246802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.